Robert P. Lyon

3.3k total citations · 2 hit papers
45 papers, 2.4k citations indexed

About

Robert P. Lyon is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Robert P. Lyon has authored 45 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 32 papers in Radiology, Nuclear Medicine and Imaging and 12 papers in Molecular Biology. Recurrent topics in Robert P. Lyon's work include Monoclonal and Polyclonal Antibodies Research (32 papers), HER2/EGFR in Cancer Research (29 papers) and Cell Adhesion Molecules Research (10 papers). Robert P. Lyon is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (32 papers), HER2/EGFR in Cancer Research (29 papers) and Cell Adhesion Molecules Research (10 papers). Robert P. Lyon collaborates with scholars based in United States and United Kingdom. Robert P. Lyon's co-authors include Peter D. Senter, Jocelyn R. Setter, Martha E. Anderson, Joshua H. Hunter, Svetlana O. Doronina, Patrick Burke, William M. Atkins, Tim D. Bovee, Mechthild Jonas and Chris Leiske and has published in prestigious journals such as Journal of the American Chemical Society, Nucleic Acids Research and Angewandte Chemie International Edition.

In The Last Decade

Robert P. Lyon

45 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

2015 390 citations Robert P. Lyon, Tim D. Bovee et al. Nature Biotechnology profile →
Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

2014 358 citations Robert P. Lyon, Jocelyn R. Setter et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert P. Lyon United States	22	1.4k	1.4k	984	340	202	45	2.4k
Wayne C. Widdison United States	17	1.8k 1.2×	1.7k 1.3×	1.1k 1.1×	493 1.4×	219 1.1×	34	2.8k
Tim D. Bovee United States	6	1.5k 1.0×	1.4k 1.0×	881 0.9×	314 0.9×	155 0.8×	10	2.2k
Martha E. Anderson United States	18	1.4k 0.9×	1.1k 0.8×	865 0.9×	280 0.8×	288 1.4×	38	2.1k
Roger F. Zabinski United States	11	1.4k 1.0×	1.2k 0.9×	808 0.8×	206 0.6×	197 1.0×	11	2.1k
Brian A. Mendelsohn United States	26	1.5k 1.0×	1.5k 1.1×	1.0k 1.0×	667 2.0×	151 0.7×	39	2.6k
Nicole M. Okeley United States	22	1.4k 1.0×	1.4k 1.0×	1.2k 1.3×	443 1.3×	316 1.6×	38	2.8k
Changshou Gao United States	29	885 0.6×	1.6k 1.2×	1.7k 1.7×	324 1.0×	422 2.1×	67	2.9k
Scott C. Jeffrey United States	16	990 0.7×	967 0.7×	777 0.8×	356 1.0×	172 0.9×	33	1.6k
Dennis R. Benjamin United States	18	1.2k 0.8×	1.0k 0.8×	1.0k 1.0×	200 0.6×	306 1.5×	41	2.3k
Brian E. Toki United States	14	1.6k 1.1×	1.4k 1.0×	1.1k 1.1×	549 1.6×	325 1.6×	15	2.9k

Countries citing papers authored by Robert P. Lyon

Since Specialization

Citations

This map shows the geographic impact of Robert P. Lyon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert P. Lyon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert P. Lyon more than expected).

Fields of papers citing papers by Robert P. Lyon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert P. Lyon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert P. Lyon. The network helps show where Robert P. Lyon may publish in the future.

Co-authorship network of co-authors of Robert P. Lyon

This figure shows the co-authorship network connecting the top 25 collaborators of Robert P. Lyon. A scholar is included among the top collaborators of Robert P. Lyon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert P. Lyon. Robert P. Lyon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moquist, Philip N., Xinqun Zhang, Chris Leiske, et al.. (2024). Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation. Bioconjugate Chemistry. 35(6). 855–866. 2 indexed citations

Gosink, John J., Michelle Ulrich, Liya Huang, et al.. (2023). Abstract 1522: SGN-B6A induces immunogenic cell death as an additional mechanism of action. Cancer Research. 83(7_Supplement). 1522–1522. 2 indexed citations

Lyon, Robert P., Mechthild Jonas, Christopher Frantz, et al.. (2023). SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications. Molecular Cancer Therapeutics. 22(12). 1444–1453. 12 indexed citations

Moquist, Philip N., Tim D. Bovee, Andrew B. Waight, et al.. (2020). Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux–positive Tumor Models. Molecular Cancer Therapeutics. 20(2). 320–328. 19 indexed citations

Simmons, Jessica K., et al.. (2020). Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation. Toxicology and Applied Pharmacology. 392. 114932–114932. 52 indexed citations

Courter, Joel R., Andrew B. Waight, Robert P. Lyon, et al.. (2020). Structure-activity relationships of tubulysin analogues. Bioorganic & Medicinal Chemistry Letters. 30(14). 127241–127241. 10 indexed citations

Zhang, Xinqun, Roma Yumul, Weiping Zeng, et al.. (2019). A coiled-coil masking domain for selective activation of therapeutic antibodies. Nature Biotechnology. 37(7). 761–765. 64 indexed citations

Neumann, Christopher S., Martha E. Anderson, Julia H. Cochran, et al.. (2018). Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 17(12). 2633–2642. 32 indexed citations

Burke, Patrick, Holden W. H. Lai, Kim K. Emmerton, et al.. (2018). Glucuronide-Linked Antibody–Tubulysin Conjugates Display Activity in MDR+ and Heterogeneous Tumor Models. Molecular Cancer Therapeutics. 17(8). 1752–1760. 15 indexed citations

10.

Lyon, Robert P.. (2018). Drawing lessons from the clinical development of antibody-drug conjugates. Drug Discovery Today Technologies. 30. 105–109. 43 indexed citations

11.

Sussman, Django, Lori Westendorf, David W. Meyer, et al.. (2018). Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability. Protein Engineering Design and Selection. 31(2). 47–54. 47 indexed citations

12.

Fu, Li, Kim K. Emmerton, Mechthild Jonas, et al.. (2016). Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Research. 76(9). 2710–2719. 231 indexed citations

13.

Burke, Patrick, Scott C. Jeffrey, Joshua H. Hunter, et al.. (2016). Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 16(1). 116–123. 110 indexed citations

14.

Burke, Patrick, Jocelyn R. Setter, Joshua H. Hunter, et al.. (2016). Development of Novel Quaternary Ammonium Linkers for Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 15(5). 938–945. 45 indexed citations

15.

Lyon, Robert P., Tim D. Bovee, Svetlana O. Doronina, et al.. (2015). Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nature Biotechnology. 33(7). 733–735. 390 indexed citations breakdown →

16.

Lyon, Robert P., Jocelyn R. Setter, Tim D. Bovee, et al.. (2014). Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nature Biotechnology. 32(10). 1059–1062. 358 indexed citations breakdown →

17.

Lyon, Robert P., David L. Meyer, Jocelyn R. Setter, & Peter D. Senter. (2011). Conjugation of Anticancer Drugs Through Endogenous Monoclonal Antibody Cysteine Residues. Methods in enzymology on CD-ROM/Methods in enzymology. 502. 123–138. 78 indexed citations

18.

McDonagh, Charlotte F., Kristine M. Kim, Eileen Turcott, et al.. (2008). Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Molecular Cancer Therapeutics. 7(9). 2913–2923. 60 indexed citations

19.

Kim, Kristine M., Charlotte F. McDonagh, Lori Westendorf, et al.. (2008). Anti-CD30 diabody-drug conjugates with potent antitumor activity. Molecular Cancer Therapeutics. 7(8). 2486–2497. 73 indexed citations

20.

Abel, Erika L., Robert P. Lyon, T K Bammler, et al.. (2004). Estradiol metabolites as isoform-specific inhibitors of human glutathione S-transferases. Chemico-Biological Interactions. 151(1). 21–32. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact